← Leaderboards
Michael Rod Zalutsky
Duke University
$18,420,913
Attributed
$20,553,545
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$20,553,545 · 12
By mechanism
R01$9,319,852 · 3
R37$3,830,496 · 1
P50$3,520,771 · 3
P01$2,240,137 · 1
P30$1,228,316 · 3
R21$413,973 · 1
Top collaborators
- Martin G Pomper10 shared
- George Sgouros5 shared
Most similar at Duke University
Same institution · by research overlap
- David Reardon$8,732,934
- Darell D Bigner$25,397,506
- John H Sampson$43,413,436
- Gerald Arthur Grant$1,632,799
- Ganesan Vaidyanathan$3,939,896
Others in their field
Top investigators on “Radiotracer”
- Robert H Mach · Wake Forest University$39,562,505
- Simon R Cherry · University Of California Los Angeles$17,948,135
- Joel Synes Perlmutter · Washington University$16,457,601
- Gwenn S Smith · Long Island Jewish Medical Center$16,008,680
- Richard E Carson · Yale University$15,174,693
- Rajesh Narendran · Columbia University Health Sciences$15,115,382
Research focus
RadiotracerLabelRadiolabeledRadioactivityTumorNeoplastic CellRadioisotopesToxic EffectRadiation TherapyRadiationGliomaBaseIn VivoDoseAntibodiesMalignant NeoplasmsNormal Tissue MorphologyIodineCytotoxicityXenograft ProcedureDesignRadiopharmaceuticalsParticleIn Vitro
Grant awards (76)
Small Molecule PSMA-Targeted Alpha Therapy$423,933
R01 · FY2023 · CA
Small Molecule PSMA-Targeted Alpha Therapy$1
R01 · FY2023 · CA
PSMAi-PARPi combination agents for the targeted Auger and alpha therapy of metastatic castration-resistant prostate cancer$413,973
R21 · FY2022 · CA · contact PI
Small Molecule PSMA-Targeted Alpha Therapy$362,164
R01 · FY2022 · CA
Small Molecule PSMA-Targeted Alpha Therapy$389,581
R01 · FY2021 · CA
Astatine And Iodine Radiolabeled Monoclonal Antibodies$455,654
R01 · FY2020 · CA · contact PI
Small Molecule PSMA-Targeted Alpha Therapy$319,250
R01 · FY2020 · CA
Astatine And Iodine Radiolabeled Monoclonal Antibodies$441,983
R01 · FY2019 · CA · contact PI
Astatine And Iodine Radiolabeled Monoclonal Antibodies$455,654
R01 · FY2018 · CA · contact PI
Small Molecule PSMA-Targeted Alpha Therapy$401,678
R01 · FY2018 · CA
Targeted Alpha-Particle Radiotheraphy of Brain Tumors with 211At-81C6 Antibody$393,701
P50 · FY2018 · CA · contact PI
Astatine And Iodine Radiolabeled Monoclonal Antibodies$455,654
R01 · FY2017 · CA · contact PI
Small Molecule PSMA-Targeted Alpha Therapy$418,621
R01 · FY2017 · CA
Targeted Radiotherapy of Neoplastic Meningitis using Monoclonal Antibodies Label$534,032
P01 · FY2016 · CA · contact PI
Astatine And Iodine Radiolabeled Monoclonal Antibodies$455,654
R01 · FY2016 · CA · contact PI
Small Molecule PSMA-Targeted Alpha Therapy$404,015
R01 · FY2016 · CA
Targeted Alpha-Particle Radiotheraphy of Brain Tumors with 211At-81C6 Antibody$312,244
P50 · FY2016 · CA · contact PI
Targeted Radiotherapy of Neoplastic Meningitis using Monoclonal Antibodies Label$546,302
P01 · FY2015 · CA · contact PI
Small Molecule PSMA-Targeted Alpha Therapy$388,423
R01 · FY2015 · CA
Targeted Alpha-Particle Radiotheraphy of Brain Tumors with 211At-81C6 Antibody$335,001
P50 · FY2015 · CA · contact PI
Targeted Radiotherapy of Neoplastic Meningitis using Monoclonal Antibodies Label$484,382
P01 · FY2014 · CA · contact PI
Small Molecule PSMA-Targeted Alpha Therapy$465,015
R01 · FY2014 · CA
Astatine And Iodine Radiolabeled Monoclonal Antibodies$450,706
R01 · FY2014 · CA · contact PI
Targeted Alpha-Particle Radiotheraphy of Brain Tumors with 211At-81C6 Antibody$331,542
P50 · FY2014 · CA · contact PI
Radiochemistry$58,487
P30 · FY2014 · CA · contact PI
Astatine And Iodine Radiolabeled Monoclonal Antibodies$440,288
R01 · FY2013 · CA · contact PI
Targeted Radiotherapy of Neoplastic Meningitis using Monoclonal Antibodies Label$330,634
P01 · FY2013 · CA · contact PI
TARGETED RADIOTHERAPHY OF BRAIN TUMORE USING MODULAR RECOMBINANT$48,305
P50 · FY2013 · NS · contact PI
Radiochemistry$35,832
P30 · FY2013 · CA · contact PI
Astatine And Iodine Radiolabeled Monoclonal Antibodies$472,247
R01 · FY2012 · CA · contact PI
Targeted Radiotherapy of Neoplastic Meningitis using Monoclonal Antibodies Label$344,787
P01 · FY2012 · CA · contact PI
TARGETED RADIOTHERAPHY OF BRAIN TUMORE USING MODULAR RECOMBINANT$48,301
P50 · FY2012 · NS · contact PI
Radiochemistry$38,407
P30 · FY2012 · CA · contact PI
Radiochemistry$2,499
P30 · FY2012 · CA · contact PI
Astatine And Iodine Radiolabeled Monoclonal Antibodies$476,220
R01 · FY2011 · CA · contact PI
TARGETED RADIOTHERAPHY OF BRAIN TUMORE USING MODULAR RECOMBINANT$53,641
P50 · FY2011 · NS · contact PI
Radiochemistry$39,248
P30 · FY2011 · CA · contact PI
Astatine And Iodine Radiolabeled Monoclonal Antibodies$492,731
R01 · FY2010 · CA · contact PI
TARGETED RADIOTHERAPHY OF BRAIN TUMORE USING MODULAR RECOMBINANT$57,807
P50 · FY2010 · NS · contact PI
Radiochemistry$42,592
P30 · FY2010 · CA · contact PI
RADIOLABELING FACILITY$71,946
P30 · FY2009 · CA · contact PI
TARGETED RADIOTHERAPHY OF BRAIN TUMORE USING MODULAR RECOMBINANT$58,413
P50 · FY2009 · NS · contact PI
Astatine and Iodine Radiolabeled Monoclonal Antibodies$448,748
R37 · FY2008 · CA · contact PI
Lutetium-177 Radiolabeled Antibodies for the Treatment of CNS Malignancies$71,658
P50 · FY2008 · NS · contact PI
RADIOLABELING FACILITY$49,142
P30 · FY2008 · CA · contact PI
Astatine and Iodine Radiolabeled Monoclonal Antibodies$449,089
R37 · FY2007 · CA · contact PI
Lutetium-177 Radiolabeled Antibodies for the Treatment of CNS Malignancies$73,806
P50 · FY2007 · NS · contact PI
RADIOLABELING FACILITY$47,942
P30 · FY2007 · CA · contact PI
Astatine and Iodine Radiolabeled Monoclonal Antibodies$453,953
R37 · FY2006 · CA · contact PI
Lutetium-177 Radiolabeled Antibodies for the Treatment of CNS Malignancies$66,287
P50 · FY2006 · NS · contact PI
RADIOLABELING FACILITY$46,776
P30 · FY2006 · CA · contact PI
Astatine and Iodine Radiolabeled Monoclonal Antibodies$453,381
R37 · FY2005 · CA
Lutetium-177 Radiolabeled Antibodies for the Treatment of CNS Malignancies$66,287
P50 · FY2005 · NS
RADIOLABELING FACILITY$45,645
P30 · FY2005 · CA
Astatine and Iodine Radiolabeled Monoclonal Antibodies$441,378
R37 · FY2004 · CA
Astatine 211 &Radioiodine Labeled Octreotide Conjugates$287,595
R01 · FY2004 · CA
Lutetium-177 Radiolabeled Antibodies for the Treatment of CNS Malignancies$210,511
P50 · FY2004 · NS
ASTATINE AND IODINE RADIOLABELED MONOCLONAL ANTIBODIES$409,472
R37 · FY2003 · CA
Astatine 211 &Radioiodine Labeled Octreotide Conjugates$287,595
R01 · FY2003 · CA
ASTATINE AND IODINE RADIOLABELED MONOCLONAL ANTIBODIES$400,306
R37 · FY2002 · CA
PRETARGETING STRATEGIES FOR CENTRAL NERVOUS MALIGNANCY RADIOIMMUNOTHERAPY$313,976
P50 · FY2002 · NS
Astatine 211 &Radioiodine Labeled Octreotide Conjugates$287,595
R01 · FY2002 · CA
CORE--RADIOLABELING$187,450
P30 · FY2002 · CA
ASTATINE AND IODINE RADIOLABELED MONOCLONAL ANTIBODIES$391,405
R37 · FY2001 · CA
PRETARGETING STRATEGIES FOR CENTRAL NERVOUS MALIGNANCY RADIOIMMUNOTHERAPY$313,976
P50 · FY2001 · NS
PRETARGETING STRATEGIES FOR CENTRAL NERVOUS MALIGNANCY RADIOIMMUNOTHERAPY$288,255
P50 · FY2001 · NS
Astatine 211 &Radioiodine Labeled Octreotide Conjugates$287,595
R01 · FY2001 · CA
CORE--RADIOLABELING$187,450
P30 · FY2001 · CA
CORE--RADIOLABELING$187,450
P30 · FY2001 · CA
CORE--RADIOLABELING$187,450
P30 · FY2001 · CA
CORE--RADIOLABELING$0
P30 · FY2001 · CA
ASTATINE AND IODINE RADIOLABELED MONOCLONAL ANTIBODIES$382,764
R37 · FY2000 · CA
PRETARGETING STRATEGIES FOR CENTRAL NERVOUS MALIGNANCY RADIOIMMUNOTHERAPY$288,255
P50 · FY2000 · NS
PRETARGETING STRATEGIES FOR CENTRAL NERVOUS MALIGNANCY RADIOIMMUNOTHERAPY$188,805
P50 · FY2000 · NS
CORE--RADIOLABELING$0
P30 · FY2000 · CA
CORE--RADIOLABELING$0
P30 · FY2000 · CA